|

You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Skip to content

Harrow® is committed to helping patients have affordable access to ZERVIATE®

To learn more about ZERVIATE access, visit harrowconnects.com

PAY AS LITTLE AS $59*

For eligible patients. Restrictions apply. See terms and conditions below.

See the efficacy data for ZERVIATE

*Terms and Conditions:

  • For patients whose prescriptions are covered by commercial insurance, use of this card may reduce your copayment so that you may pay as little as $59.

  • For patients whose prescriptions are not covered by either commercial insurance or Medicare, use of this card may reduce your cost for prescriptions to as little as $59.

  • This card is not valid for prescriptions paid for in part or full by Medicare, Medicaid, Tricare, DOD, VA, or any state or federally funded program.

  • By enrolling in the Harrow Savings Program, you certify to the following: (1) Your Medicare plan does not cover your Harrow prescription medication; (2) you will not seek any prescription coverage or reimbursement from your Medicare plan for the the cost of the Harrow prescriptions received through this offer or report any amounts paid in connection with this offer toward your True Out-of-Pocket (TrOOP) costs under your plan; (3) that you will purchase all Harrow prescriptions covered under this offer during the calendar year by using the Harrow Savings Program and will not use your Medicare benefits even if your benefits change

  • This program is subject to overall maximum support amounts.

  • This offer shall be applied only toward the cost of an eligible prescription product and not toward ancillary services or treatment costs.

  • This offer is only good in the United States of America (including the District of Columbia, Puerto Rico, Guam, and the U.S. Virgin Islands).

  • You must present this coupon along with your prescription to participate in this program.

  • This offer is not health insurance.

  • The selling, trading, or counterfeiting of this coupon is prohibited by law. Void if reproduced.

  • This offer is not transferable.

  • When you use this offer, you are certifying that you understand and agree to comply with the program rules, regulations, eligibility requirements, and Terms and Conditions.

  • Harrow Health reserves the right to rescind, revoke, or amend this offer at any time.

For questions call: 1-316-219-4495

INDICATIONS AND USAGE

ZERVIATE® (cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis.

DOSAGE AND ADMINISTRATION

Instill one drop of ZERVIATE in each affected eye twice daily (approximately 8 hours apart).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Contamination of Tip and Solution: As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container to avoid injury to the eye and to prevent contaminating the tip and solution. Keep the multi-dose bottle closed when not in use. Discard the single-use container after using in each eye.

Contact Lens Wear: Patients should be advised not to wear a contact lens if their eye is red. ZERVIATE should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of ZERVIATE. The preservative in ZERVIATE, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes following administration of ZERVIATE.

ADVERSE REACTIONS

The most commonly reported adverse reactions occurred in approximately 1%–7% of patients treated with either ZERVIATE or vehicle. These reactions were ocular hyperemia, instillation site pain, and visual acuity reduced.

Please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Contamination of Tip and Solution: As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container to avoid injury to the eye and to prevent contaminating the tip and solution. Keep the multi-dose bottle closed when not in use. Discard the single-use container after using in each eye.

Contact Lens Wear: Patients should be advised not to wear a contact lens if their eye is red. ZERVIATE should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of ZERVIATE. The preservative in ZERVIATE, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes following administration of ZERVIATE.

ADVERSE REACTIONS

The most commonly reported adverse reactions occurred in approximately 1%–7% of patients treated with either ZERVIATE or vehicle. These reactions were ocular hyperemia, instillation site pain, and visual acuity reduced.

Please see the full Prescribing Information.